Sanofi-Aventis prevails again over Impax on Rilutek patent
This article was originally published in Scrip
Executive Summary
Sanofi-Aventishas prevailed again over Impax Laboratoriesin US patent litigation and thus thwarted the generics firm's efforts to sell a version of the innovator's amyotrophic lateral sclerosis (ALS) therapy, Rilutek (riluzole).